Contraceptive Technology Update
RSSArticles
-
Do Teen LARC Users Get Message on Condom Use?
Family planning providers are seeing an increase in adolescent use of long-acting reversible contraceptive methods. Efforts to improve LARC access to adolescents seeking contraception at Title X service sites have increased their use.
-
Review reproductive health considerations for women with inflammatory bowel disease
Between 1 and 1.4 million people in the United States have inflammatory bowel disease, a group of conditions that includes Crohn’s disease and ulcerative colitis. For women of childbearing age with IBD, there are considerations related to fertility and pregnancy, according to recent information presented by the Association of Reproductive Health Professionals.
-
FDA Updates Mifepristone Labeling, Easing Access to Abortion Pill
The Food and Drug Administration has approved new and updated labeling for the medication abortion drug mifepristone (Mifeprex, Danco Laboratories, New York City) to reflect the most current clinical practices and safety and efficacy data. The drug’s new label reduces the size of the initial dose and extends the window for taking it to 70 days since the first day of a woman’s last menstrual period.
-
What’s in the Pipeline? Science Moves Long-acting Contraceptive Options Forward
With the growth in interest in long-acting reversible contraceptive methods, what new options may be available to U.S. women?
-
Zika Virus Update — What Do Your Patients Need to Know?
Approximately four in 10 (42%) U.S. adults in households in which someone is pregnant or considering becoming pregnant don’t realize the Zika virus can be sexually transmitted, according to results from a new national survey. The poll is part of an ongoing series of surveys focused on the public’s response to public health emergencies by the Harvard Opinion Research Program at the Boston-based Harvard T.H. Chan School of Public Health.
-
Check coding for intrauterine devices
As of Jan. 1, 2016, the Centers for Medicare & Medicaid Services has discontinued use of HCPCS code J7302 for 52 mg levonorgestrel-releasing IUDs.
-
Access resource on LARC reimbursement
Obtain appropriate compensation for long-acting reversible contraceptive services with Intrauterine Devices and Implants: A Guide to Reimbursement, a new guide created by the American College of Obstetricians and Gynecologists’ long-acting reversible contraceptive Program, the National Health Law Program, the National Women’s Law Center, the National Family Planning and Reproductive Health Association, and the Bixby Center at the University of California, San Francisco.
-
Counsel your patients on their risk for pregnancies that are exposed to alcohol
The latest statistics from Centers for Disease Control and Prevention indicate that more than 3 million women between the ages of 15 and 44 are at risk of exposing their developing babies to alcohol because they are drinking and not using birth control to prevent pregnancy.1 The report also found that three in four women who want to get pregnant as soon as possible do not stop drinking alcohol when they stop using birth control.1
-
Management of your patients’ menopause — Is your care on the right track?
By 2020, more than 50 million U.S. women will be older than 51, the mean age when menopause occurs. Despite the availability of effective hormonal and nonhormonal treatments for menopausal symptoms, few women with menopausal symptoms are evaluated or treated, reports a new scientific perspective.
-
Teen dating violence: Why you should screen
According to the Centers for Disease Control and Prevention, among high school students who date, 21% of females and 10% of males experience physical and/or sexual dating violence.